Halliburton Labs has added three energy tech startups to its program. Photo via Getty Images

Halliburton Labs has announced its latest cohort — and revealed details about its next pitch day.

The program, housed at Halliburton's facilities in Houston, added FuelX, LiNa Energy, and Solaires Entreprises to the clean energy accelerator. The companies will receive support from mentors from within Halliburton's workforce and network, as well as go through the accelerator's programming.

“We’re excited to support FuelX, LiNa Energy, and Solaires with the tools they need to achieve their goals,” says Halliburton Labs Managing Director Dale Winger in a news release. “Each participant company receives customized support to enable efficient use of their time and capital by engaging Halliburton’s scaling experience and capabilities.”

The next Halliburton Labs will not take place in Houston. The program is going on the road to host its next Halliburton Labs Finalists Pitch Day on Thursday, September 21, in Denver. The event will be a part of the inaugural Energy Tech Day at Denver Startup Week and will include pitches from innovative, early-stage energy tech companies.

FuelX

FuelX, which has a production plant in the Houston area, manufactures hydrogen storage materials and fuel cell power systems with alane solid state hydrogen fuel.

“Participation in the Halliburton Labs program accelerates our ability to scale to meet existing military and commercial project milestones,” says Greg Jarvie, co-founder and CEO of FuelX.

LiNa Energy

Headquartered in Lancaster, England, LiNa Energy develops and provides low-cost, solid-state sodium batteries.

"LiNa is delighted to be selected for Halliburton Labs – the support and investment will accelerate LiNa's growth on a scale found only in the energy industry,” says Chief Commercial Officer Will Tope. “Halliburton Labs is a cornerstone of our strategy, as we scale up manufacturing to deliver bigger energy storage systems to our partners around the world."

Solaires Entreprises

Solaires Entreprises, based in Victoria, British Columbia, is developing lightweight, flexible, efficient, and transparent solar cells.

“Our company is purpose-driven toward what our technology can achieve: a more affordable and reliable alternative within solar energy and photovoltaics and where renewables become a bigger portion of the world power mix,” says Solaires Co-founder and Chief Science Officer Sahar Sam.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.